Notice of Closed Meeting, 1976-1977 [2021-00282]
Download as PDF
<![CDATA[
1976
Federal Register / Vol. 86, No. 6 / Monday, January 11, 2021 / Notices
Institute for Occupational Safety and
Health, 1095 Willowdale Road, Mailstop
1811, Morgantown, West Virginia
26505, Telephone: (304) 285–5879.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–00283 Filed 1–8–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–IP–21–001, Promoting the
Importance of Infant and Childhood
Vaccination Among Pregnant Women by
Prenatal Care Providers; and RFA–IP–
21–002, US Enhanced Surveillance
Network to Assess Burden, Natural
History, and Effectiveness of Vaccines to
Prevent Enteric and Respiratory Viruses
in Children.
Date: April 13–14, 2021.
Time: 10:00 a.m.–5:00 p.m., EDT.
Place: Teleconference, Centers for
Disease Control and Prevention, Room
22:36 Jan 08, 2021
Jkt 253001
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Marilyn Ridenour B.S.N., M.B.A.,
M.P.H., C.P.H., C.I.C., CAPT, USPHS,
Scientific Review Officer, CDC, National
Institute for Occupational Safety and
Health, 1095 Willowdale Road, Mailstop
1811, Morgantown, West Virginia
26505, Telephone: (304) 285–5879.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–00281 Filed 1–8–21; 8:45 am]
[FR Doc. 2021–00285 Filed 1–8–21; 8:45 am]
BILLING CODE 4163–18–P
Notice of Closed Meeting
VerDate Sep<11>2014
1080, 8 Corporate Square Boulevard,
Atlanta, Georgia 30329–4027.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road, NE, Mailstop US8–1,
Atlanta, Georgia 30329–4027, (404) 718–
8833, ganderson@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
Funding Opportunity Announcement
(FOA), RFA OH–21–003, Extension of
the World Trade Center Health Registry
(U50).
Date: April 13, 2021.
Time: 9:00 a.m.–6:00 p.m., EDT.
Place: Virtual.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–IP–21–003, Collaborative Research
on Influenza, Coronavirus Disease 2019
(COVID–19), and Other Respiratory
Pathogens in South Africa.
Date: May 13, 2021.
Time: 10:00 a.m.–5:00 p.m., EDT.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
E:\FR\FM\11JAN1.SGM
11JAN1
Federal Register / Vol. 86, No. 6 / Monday, January 11, 2021 / Notices
Place: Teleconference, Centers for
Disease Control and Prevention, Room
1080, 8 Corporate Square Boulevard,
Atlanta, Georgia 30329–4027.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road, NE, Mailstop US8–1,
Atlanta, Georgia 30329–4027, (404) 718–
8833, ganderson@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–00282 Filed 1–8–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0001]
Proposed Revised Vaccine Information
Materials
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
Under the National
Childhood Vaccine Injury Act (NCVIA),
the Centers for Disease Control and
Prevention (CDC) within the
Department of Health and Human
Services (HHS) develops vaccine
information materials that all health
care providers are required to give to
patients/parents prior to administration
of specific vaccines. HHS/CDC seeks
written comment on proposed updated
vaccine information statements for
vaccines covered by the National
Vaccine Injury Compensation Program
(VICP).
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
Written comments must be
received on or before March 12, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0001, by any of the following methods:
DATES:
VerDate Sep<11>2014
22:36 Jan 08, 2021
Jkt 253001
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Written comments should be
addressed to Suzanne Johnson-DeLeon
(VISComments@cdc.gov), National
Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention,
Mailstop H24–6, 1600 Clifton Road NE,
Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
docket number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Suzanne Johnson-DeLeon, National
Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention,
Mailstop H24–6, 1600 Clifton Road NE,
Atlanta, Georgia 30329; VISComments@
cdc.gov.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
develop and disseminate vaccine
information materials for distribution by
all health care providers in the United
States to any patient (or to the patient’s
parent or legal representative in the case
the patient is a child) receiving vaccines
covered under the National Vaccine
Injury Compensation Program (VICP).
Development and revision of the
vaccine information materials, also
known as vaccine information
statements (VISs), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
period, and in consultation with the
Advisory Commission on Childhood
Vaccines, appropriate health care
provider and parent organizations, and
the Food and Drug Administration. The
law also requires that the information
contained in the materials be based on
available data and information, be
presented in understandable terms, and
include:
(1) A concise description of the
benefits of the vaccine,
(2) A concise description of the risks
associated with the vaccine,
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
1977
(3) A statement of the availability of
the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as
may be determined by the Secretary.
The vaccines initially covered under
the National Vaccine Injury
Compensation Program were diphtheria,
tetanus, pertussis, measles, mumps,
rubella and poliomyelitis vaccines.
Since April 15, 1992, any health care
provider in the United States who
intends to administer one of these
covered vaccines is required to provide
copies of the relevant vaccine
information materials prior to
administration of any of these vaccines.
Since then, the following vaccines have
been added to the National Vaccine
Injury Compensation Program, requiring
provision of vaccine information
materials before vaccine administration
for them as well: Hepatitis B,
Haemophilus influenzae type b (Hib),
varicella (chickenpox), pneumococcal
conjugate, rotavirus, hepatitis A,
meningococcal, human papillomavirus
(HPV), and seasonal influenza vaccines.
Instructions for use of the vaccine
information materials are found on the
CDC website at: https://www.cdc.gov/
vaccines/hcp/vis/.
CDC is proposing updated versions to
simplify, streamline, and standardize
the content and formatting of the
vaccine information statements.
As proposed, each of the updated
VISs contains the same seven sections.
Formatting of the documents is
identical, using the same fonts and
layout.
Section 1 (‘‘Why get vaccinated?’’)
provides an overview of the disease(s)
prevented by the vaccine. This section
is being updated to provide a clearer,
more plain-language description of the
disease and its impact.
Section 2 (e.g., ‘‘Hepatitis A vaccine’’)
describes the vaccine and
recommendations for its use. A general
description of the usually-recommended
schedule is provided and groups of
people for whom the vaccine is
typically recommended are identified.
Updates to the text in this section
remove some of the more specific
details related to schedules and
numbers of doses, which can vary
depending on an individual patient’s
circumstances.
Section 3 (‘‘Talk with your health care
provider’’) highlights conditions and
medical history that should be brought
to the vaccine provider’s attention when
deciding whether the vaccine is
appropriate for an individual patient.
Previously entitled ‘‘Some people
should not get this vaccine,’’ this
section has been refocused to be broader
E:\FR\FM\11JAN1.SGM
11JAN1
]]>Agencies
[Federal Register Volume 86, Number 6 (Monday, January 11, 2021)]
[Notices]
[Pages 1976-1977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-00282]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--RFA-IP-21-003, Collaborative
Research on Influenza, Coronavirus Disease 2019 (COVID-19), and Other
Respiratory Pathogens in South Africa.
Date: May 13, 2021.
Time: 10:00 a.m.-5:00 p.m., EDT.
[[Page 1977]]
Place: Teleconference, Centers for Disease Control and Prevention,
Room 1080, 8 Corporate Square Boulevard, Atlanta, Georgia 30329-4027.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600 Clifton Road, NE, Mailstop US8-1,
Atlanta, Georgia 30329-4027, (404) 718-8833, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-00282 Filed 1-8-21; 8:45 am]
BILLING CODE 4163-18-P
